Imipenem/Cilastatine Hikma

Imipenem/cilastatin, the active ingredient in Imipenem/Cilastatine Hikma, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections, including intra‑abdominal, urinary tract, respiratory, skin and soft‑tissue, and bloodstream infections, primarily in hospitalized adult patients.

GNH USA supplies Imipenem/Cilastatine Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Imipenem/cilastatin is used for severe bacterial infections that require broad‑spectrum intravenous therapy.

- Complicated intra‑abdominal infections: provides rapid bacterial eradication and clinical cure. - Complicated urinary tract infections: eliminates resistant Gram‑negative and Gram‑positive pathogens. - Nosocomial pneumonia: offers coverage against multidrug‑resistant organisms in ventilated patients. - Skin and soft tissue infections: treats deep or extensive infections caused by susceptible bacteria. - Septicemia: delivers bactericidal activity in systemic bloodstream infections.

Adverse reactions may occur with any intravenous antibiotic and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Injection site pain: local discomfort at the infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: severe diarrhea with pseudomembranous colitis. - Anaphylaxis: acute, potentially life‑threatening hypersensitivity. - Stevens‑Johnson syndrome: severe mucocutaneous reaction.

Use of Imipenem/Cilastatine Hikma requires careful clinical assessment and monitoring.

- Assess renal function: adjust dosing in patients with impaired clearance. - Monitor for seizures: avoid in patients with a history of epilepsy. - Evaluate for hypersensitivity: discontinue if an allergic reaction occurs. - Use caution in CNS disorders: increased risk of neurotoxicity. - Adjust dose in renal impairment: follow renal dosing guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Imipenem/cilastatin can interact with several concomitant medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: reduces valproate levels, risking seizure breakthrough. - Probenecid: decreases renal clearance, increasing imipenem exposure. - Cyclosporine: heightened nephrotoxicity risk.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate neurotoxic effects. - Aminoglycosides: combined renal toxicity requires renal function monitoring.